Jonas Jarvius has informed Q-linea AB:s (publ) board of directors that he plans to step down as CEO before summer 2024 to take over as CEO of a US based life science company. Three of the major shareholders of Q-linea (69% of the shares) has informed the Board of Directors of its intention to support Jonas Jarvius as a new board member in 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 SEK | -1.49% | -10.60% | -37.30% |
26/04 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
13/03 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.30% | 24.86M | |
-15.43% | 18.51B | |
-40.81% | 2.85B | |
+19.34% | 1.95B | |
+2.22% | 1.72B | |
+28.27% | 1.26B | |
-9.56% | 1.02B | |
-16.29% | 950M | |
+0.07% | 777M | |
-22.49% | 643M |
- Stock Market
- Equities
- QLINEA Stock
- News Q-linea AB
- Q-Linea AB Announces Jonas Jarvius to Step Down as CEO Before Summer 2024